Trial Profile

Phase II Trial of Natalizumab (Tysabri) Plus Prednisone for Initial Therapy of Acute Graft Versus Host Disease (aGVHD) of the Gastrointestinal Tract

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 11 Sep 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Natalizumab (Primary) ; Methylprednisolone
Indications Graft-versus-host disease
Focus Therapeutic Use

Most Recent Events

08 Sep 2020 Primary endpoint (GVHD-free survival rate) has not been met.
08 Sep 2020 Status changed to discontinued.
08 Sep 2020 Results published in the Bone Marrow Transplantation.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com